BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program
BioNTech SE (Nasdaq: BNTX) is set to hold a press conference on December 2, 2020, focusing on the status of its lead COVID-19 vaccine candidate, BNT162b2. The conference, conducted in English, will begin at 12:30 PM CET (6:30 AM ET), and will allow journalists to submit questions online. BioNTech, a pioneer in next-generation immunotherapy, is developing various mRNA vaccine candidates for infectious diseases while continuing its oncology pipeline. More details can be found on BioNTech's official website.
- Significant focus on the status update of COVID-19 vaccine candidate BNT162b2.
- Strong positioning as a leading company in the immunotherapy sector with a broad oncology product lineup.
- None.
Mainz, Germany, December 02, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2. The event will be held in English:
International press conference at 12.30pm CET / 6.30am ET
Please register here.
Interested journalists may dial in 10-15 minutes before the conference starts. They will be able to submit questions via an online tool.
Participants may also access the press conference, including the video webcast, on https://biontech.de/ under "Events & Presentations" in the Investor & Media section of the website. A recording of the press conference will be available on the same day. Additional media materials including images and videos can be accessed through the following link: press kit.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit www.BioNTech.de.
BioNTech Contacts
Media Relations
Jasmina Alatovic
Director External Communications
+49 (0)6131 9084 1513 or +49 (0)89 62 81 75 46
Media@biontech.de
Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
+49 (0)6131 9084 1074
Investors@biontech.de
FAQ
What is the purpose of the BioNTech press conference on December 2, 2020?
What time does the BioNTech press conference start on December 2, 2020?
Where can I find more information about the BioNTech press conference?
What is the stock symbol for BioNTech?
What technologies is BioNTech developing for cancer treatment?
